Related Experiment Videos
Technology evaluation: DCVax, Northwest Biotherapeutics
1University of Washington, Tumor Vaccine Group, Seattle 98195, USA. kknutson@u.washington.edu
Abstract:
DCVax, a dendritic cell-based immunotherapy, is an active immunization platform being developed by Northwest Biotherapeutics for the potential treatment of multiple malignancies, including hormone-refractory metastatic prostate cancer, non-small-cell lung cancer, renal cancer and glioblastoma multiforme. The DCVax platform is tailored to a specific cancer type with either purified tumor-specific antigen or tumor cell extracts derived from patients at the time of resection. Phase I/II clinical trials of DCVax-Prostate have been completed, and phase III clinical trials have recently been initiated. DCVax-Brain is currently undergoing phase II clinical trials, and DCVax-Lung recently received approval from the US FDA for phase I clinical trials.
Insights
Northwest Biotherapeutics is developing DCVax, a dendritic cell-based immunotherapy, for various cancers. Clinical trials are underway for DCVax-Prostate, DCVax-Brain, and DCVax-Lung, targeting multiple malignancies.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Dendritic cell-based immunotherapy represents a novel approach to cancer treatment.
- Northwest Biotherapeutics is developing DCVax, an active immunization platform, for multiple cancer types.
Purpose of the Study:
- To summarize the development status and clinical trial progress of DCVax for various malignancies.
- To highlight the personalized nature of the DCVax platform in cancer treatment.
Main Methods:
- DCVax platform utilizes purified tumor-specific antigens or tumor cell extracts tailored to individual cancer types.
- Clinical trials, including Phase I/II, II, and III, are being conducted for different DCVax formulations (Prostate, Brain, Lung).
Main Results:
- Phase I/II trials for DCVax-Prostate are complete, with Phase III trials initiated.
- DCVax-Brain is currently in Phase II clinical trials.
- DCVax-Lung has received FDA approval for Phase I clinical trials.
Conclusions:
- DCVax is a promising dendritic cell-based immunotherapy platform with ongoing clinical development across several cancer types.
- The platform's personalized approach and active immunization strategy warrant continued investigation in oncology.